Holland, Michigan-based CraftCo. Brands has a diverse portfolio of craft spirits comprised of more than 30 spirits and liqueurs across the bourbon, gin, vodka, rye, and ready-to-drink categories. However, Bloomberg Intelligence notes that the use of weight-loss drugs stand to deepen alcohol's demand slump in the US and Europe, as moderation and wellness trends gain ground. 
Ali Anderson, the CEO of CraftCo., discusses the outlook for the spirits industry for 2026 and beyond, as well as changing consumer habits when it comes to consumption levels. Ali speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

Holland, Michigan-based CraftCo. Brands has a diverse portfolio of craft spirits comprised of more than 30 spirits and liqueurs across the bourbon, gin, vodka, rye, and ready-to-drink categories. However, Bloomberg Intelligence notes that the use of weight-loss drugs stand to deepen alcohol's demand slump in the US and Europe, as moderation and wellness trends gain ground. Ali Anderson, the CEO of CraftCo., discusses the outlook for the spirits industry for 2026 and beyond, as well as changing consumer habits when it comes to consumption levels. Ali speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

Listen for reporting from the magazine that helps global leaders stay ahead. 

Hosts Carol Massar and Tim Stenovec bring you insight on the people, companies and trends shaping today's complex economy.  You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET: http://bit.ly/3vTiACF. 

Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec bring you insight on the people, companies and trends shaping today's complex economy.&nbsp; You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.&nbsp;

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

CraftCo. CEO on the Alcohol Business Outlook 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/630c89b2-ff9b-4263-abce-b3a801740f35/transcript

Money manager Danny Moses, immortalized in The Big Short, said last week that private credit and private equity firms’ push into retail products reminds him of the years preceding the subprime mortgage crisis. The comments, made during a panel at the iConnections Global Alts conference in Miami Beach, Florida, came as business development companies — funds that pool direct loans — face a surge in redemptions amid growing concerns over lending standards. Private capital firms have begun to more aggressively court individual investors in recent years, fueling worries that a wave of withdrawals from mom-and-pop savers could strain a market built on hard-to-sell assets.

Moses, the Founder of Moses Ventures, LLC, expands on his credit market commentary and delves into the business of prediction markets, while also reacting to expansive remarks from JPMorgan CEO Jamie Dimon about the investing environment amid renewed military conflict in the Middle East. Danny speaks with Carol Massar, Tim Stenovec and Bloomberg News Equities Reporter Alexandra Semenova on Bloomberg Businessweek Daily.

Money manager Danny Moses, immortalized in The Big Short, said last week that private credit and private equity firms&rsquo; push into retail products reminds him of the years preceding the subprime mortgage crisis. The comments, made during a panel at the iConnections Global Alts conference in Miami Beach, Florida, came as business development companies &mdash; funds that pool direct loans &mdash; face a surge in redemptions amid growing concerns over lending standards. Private capital firms have begun to more aggressively court individual investors in recent years, fueling worries that a wave of withdrawals from mom-and-pop savers could strain a market built on hard-to-sell assets. Moses, the Founder of Moses Ventures, LLC, expands on his credit market commentary and delves into the business of prediction markets, while also reacting to expansive remarks from JPMorgan CEO Jamie Dimon about the investing environment amid renewed military conflict in the Middle East. Danny speaks with Carol Massar, Tim Stenovec and Bloomberg News Equities Reporter Alexandra Semenova on Bloomberg Businessweek Daily.

"Big Short" Legend Danny Moses on Dimon, Private Credit, Prediction Markets 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/3cf5f6e9-3160-4eb9-a15e-b4010173f5fa/transcript

The people, companies and trends shaping the global economy.
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.

Oil surged as the Iran war threatened to snarl shipping lanes, stoking inflation fears that pummeled bonds amid diminishing odds for a rate cut. The dollar rose. Stocks erased losses.
Also weighing on Treasuries were figures showing manufacturing expanded, with input prices jumping. Ten-year yields headed toward their biggest advance since April. The S&P 500 was little changed after a slide that earlier topped 1%. Energy and defense shares gained. Several tech firms with solid balance sheets rallied. Airlines sank. Gold topped $5,300.

The near halt to traffic through the Strait of Hormuz and disruption at a big refinery in Saudi Arabia underscored the threat to oil supplies. West Texas Intermediate jumped 6.3% to settle at $71.23. European natural gas prices soared as Qatar shut the world’s largest LNG export plant.

As US-Israeli strikes on Iran reverberated across the Middle East, President Donald Trump called on the nation’s leaders to capitulate, while the Islamic Republic’s security chief ruled out negotiations. US Defense Secretary Pete Hegseth rejected the idea of an “endless” war.

Today's show features:
Michael Contopoulos, Deputy Chief Investment Officer at Richard Bernstein Advisors, on the equity and fixed income market reaction to the latest armed conflict in the Middle East
Mona Yacoubian, Director and Senior Adviser, Middle East Program at the Center for Strategic and International Studies, on the major Middle East escalation as the US and Israel battle against Iran and its proxies
Marcelo P. Lima, Founder and Managing Partner at Heller House, on the threat of AI to fintech jobs following Block’s 40% staff reduction
Cole Smead, Chief Executive Officer and Portfolio Manager of Smead Capital Management, on the energy market reaction to the military action across the Middle East

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>. Oil surged as the Iran war threatened to snarl shipping lanes, stoking inflation fears that pummeled bonds amid diminishing odds for a rate cut. The dollar rose. Stocks erased losses. Also weighing on Treasuries were figures showing manufacturing expanded, with input prices jumping. Ten-year yields headed toward their biggest advance since April. The S&amp;P 500 was little changed after a slide that earlier topped 1%. Energy and defense shares gained. Several tech firms with solid balance sheets rallied. Airlines sank. Gold topped $5,300. The near halt to traffic through the Strait of Hormuz and disruption at a big refinery in Saudi Arabia underscored the threat to oil supplies. West Texas Intermediate jumped 6.3% to settle at $71.23. European natural gas prices soared as Qatar shut the world&rsquo;s largest LNG export plant. As US-Israeli strikes on Iran reverberated across the Middle East, President Donald Trump called on the nation&rsquo;s leaders to capitulate, while the Islamic Republic&rsquo;s security chief ruled out negotiations. US Defense Secretary Pete Hegseth rejected the idea of an &ldquo;endless&rdquo; war. Today's show features:
<ul>
<li>Michael Contopoulos, Deputy Chief Investment Officer at Richard Bernstein Advisors, on the equity and fixed income market reaction to the latest armed conflict in the Middle East</li>
<li>Mona Yacoubian, Director and Senior Adviser, Middle East Program at the Center for Strategic and International Studies, on the major Middle East escalation as the US and Israel battle against Iran and its proxies</li>
<li>Marcelo P. Lima, Founder and Managing Partner at Heller House, on the threat of AI to fintech jobs following Block&rsquo;s 40% staff reduction</li>
<li>Cole Smead, Chief Executive Officer and Portfolio Manager of Smead Capital Management, on the energy market reaction to the military action across the Middle East</li>
</ul>

Treasuries Sink as Oil Jumps on Iran War, Stoking Inflation Fears

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/6a93a41b-1066-4db2-a419-b40101716338/transcript

Vir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity.

Marianne De Backer, Ph.D., the CEO at Vir Bio, discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

Vir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity. Marianne De Backer, Ph.D., the CEO at Vir Bio, discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

Vir Bio's Cancer Treatment Progress Driving Shares Hight 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/98a32413-f1fb-44b1-803a-b3fe016dbcbb/transcript

CraftCo. CEO on the Alcohol Business Outlook

In 1 playlist(s)

Bloomberg Businessweek

Social links

Follow podcast

Recent clips